Study of Immuno-histochemical Marker Her2/neu Receptor in ovarian neoplasms

Geeta Pachori; Saroj Pachori; Anjana Choudhary; Vivek Mavaliya; Govind Sharma

Volume : X, Issue : V, May - 2020

Study of Immuno-histochemical Marker Her2/neu Receptor in ovarian neoplasms

Geeta Pachori, Saroj Pachori, Anjana Choudhary, Vivek Mavaliya, Govind Sharma

Abstract :

Among genital malignancies, Ovarian Cancer has the most increased mortality rate. HER2/neu expression levels depend on tumour histologic grade and stage of disease and are variable between tumours of the same grade. We studied the clinicopathological parameters in ovarian tumours with reference to age, histologic type and grade and their correlation with HER2/neu status. The prospective study of 2 ½ years was conducted on 100 resected ovarian tumour specimens from June 2017 to December 2019 received in the Department of Pathology, JLN Medical College, Ajmer. Sections were stained and examined for presence of ovarian tumour, Histological type, grade and forHER2/neu status, immunohistochemistry was done. Out of 100 cases, 72 cases were benign, 03 cases were borderline and 25 cases were malignant. 60% were of surface epithelial neoplasm, followed by germ cell tumors. Serous tumors were most common among all epithelial tumors (61%). Malignant cases showed maximum100% positivity withHER2. HER2/neu positivity in serous epithelial tumors was 90% and in mucinous tumors was10%. Majority of positiveHER2/neu receptors was observed in Age groups of >40 years as 85%. HER2/neu positivity seen in higher grade and stage tumors as 70% in grade 3 and stage 3 tumors respectively.The higher expression of HER–2/Neu is associated with progression of invasive cancer, higher grade and stage of ovarian tumors, higher age group, and mulitparity.